Switchboard Health Buys Livara, Raises $5M+ for MSK Care

The referral is where a health system records the decision. It is not where the patient's outcome gets decided.

On August 25, 2026, Switchboard Health announced that it acquired Livara Health and closed an oversubscribed equity round of more than $5M. The transaction gives Switchboard a virtual-first musculoskeletal care model to place behind the referral-management and care-navigation software it already sells to providers and health plans.

The logic is straightforward and the execution is not. Switchboard wants to move from helping patients find specialty care to delivering part of that care, starting with Livara's value-based MSK program. Purchase price, consideration, valuation, and closing mechanics were not disclosed, so the $5M+ financing should not be confused with the acquisition price.

What Switchboard Health Acquired

Livara Health, formerly known as SpineZone, combines care planning, virtual-first care delivery, navigation, physicians, physical therapists, psychosocial support, and escalation to specialists. Its treatment model dates to 2005, when orthopedic surgeon Kamshad Raiszadeh began developing a nonoperative approach to spine and musculoskeletal care.

Livara's value to Switchboard is not a library of exercises or another logo for a partner directory. It is a clinical operating model that can accept patients after a referral, determine the appropriate pathway, support treatment, and measure what happened. That capability moves Switchboard closer to a closed loop between the primary-care decision, specialty-care enrollment, clinical delivery, and cost outcome.

Switchboard says its provider and health-plan clients will be able to enroll eligible patients in Livara through the same referral workflow. If that integration works as described, the transaction reduces one of specialty care's most stubborn handoffs: the gap between identifying an appropriate option and getting the patient into an effective course of care.

Why This Changes Switchboard's Business

Switchboard launched in 2022 with software and a national virtual-specialty network designed to help payers, providers, employers, and risk-bearing organizations connect patients to high-value specialists. The company has since pushed deeper into the workflow, using referral management, data, and navigation to improve who gets sent where.

The Livara acquisition changes the accountability boundary. A navigation company can recommend a provider and measure whether the referral was completed. A care-delivery business is responsible for clinical engagement, pathway quality, patient adherence, and outcomes that buyers may connect directly to total cost.

That shift makes the combined proposition more valuable if Switchboard can deliver it consistently. It also makes the company harder to operate. Software integration, clinical governance, care-team continuity, payer contracting, and outcome measurement now have to work together rather than appearing as separate modules on a product page.

The Evidence Behind Livara's Model

Livara's most useful evidence comes with enough detail to avoid the usual digital-health victory lap. A 2024 Validation Institute review examined a Livara and Carelon Back and Joint Pain Program and found that participant MSK spend was 43% lower than nonparticipant spend during the post-program year. More than 75% of the difference came from lower inpatient and outpatient surgery use.

That result is meaningful because surgery utilization is one of the expensive consequences MSK programs claim they can influence. It is also bounded evidence, not a guarantee. The review applies to the studied program and population; Switchboard still has to show that the economics and clinical outcomes carry into a larger, integrated referral environment.

Livara has operated through both virtual and in-person pathways. Its own public materials say the company uses data from more than 100,000 patients to tailor care plans and combines risk stratification, self-assessment, coaching, formal evaluation, multidisciplinary review, and outcome tracking. Those are company descriptions, but they show why Switchboard bought an operating model rather than building a referral destination from scratch.

The $5M+ Financing and the People Behind the Deal

Switchboard closed an oversubscribed equity round of more than $5M alongside the acquisition. The company named First Trust Capital Partners, Route 66 Ventures, A1 Health Ventures, Allumia Ventures, and Martin Ventures as new and returning participants, but did not identify a lead investor or disclose a valuation.

The investor overlap matters. A1 Health Ventures led Livara's $15M Series B in 2024, while Martin Ventures also participated. First Trust Capital Partners led Switchboard's $6.5M seed financing announced in 2024, with Route 66 Ventures among the participating investors. The new round therefore includes firms already familiar with one or both sides of the combination.

Derek Baird, Switchboard's co-founder and CEO, says patient volume through the platform increased 500% over the previous nine months. The metric is company-reported, but it gives the transaction an operating context: more referrals create more opportunity and more risk at the handoff into care. Livara founder and CMO Kamshad Raiszadeh and CEO Rob Cohen bring the clinical history and care-delivery experience that Switchboard now has to integrate without sanding off the parts that produced results.

What the Acquisition Signals for Digital MSK Care

Virtual MSK care is not an empty category. The market includes companies with national employer and health-plan relationships, established digital programs, and significant capital. Switchboard is making a narrower strategic bet: the referral workflow itself can become the distribution and coordination layer for value-based MSK delivery.

That approach could appeal to health plans and risk-bearing providers that are tired of buying disconnected point solutions. A patient can be identified in primary care, matched inside the existing workflow, enrolled into a clinical pathway, and tracked through outcomes. The sale becomes less about app engagement and more about whether the combined system reduces leakage, avoidable utilization, and total cost.

Switchboard has already used acquisition to deepen its platform. In 2025, it acquired Conduce Health to add predictive analytics and patient-specialist matching. Livara takes the company further downstream, from improving the decision about where care should happen toward accepting responsibility for delivering some of it.

What Buyers and Investors Should Watch Next

The first proof point is integration, not another funding headline. Switchboard needs to show that an EHR referral can become a completed Livara enrollment without losing clinical context, confusing the patient, or creating new administrative work for the provider. It also needs to preserve the multidisciplinary care model while handling a larger stream of patients.

The next scorecard should include referral-to-enrollment conversion, patient completion, time to care, surgical utilization, total MSK spend, clinical outcomes, and buyer retention. Those measures will determine whether Switchboard bought a durable care-delivery capability or merely moved the difficult part of specialty care onto its own balance sheet.

The transaction gives Switchboard more control over the patient journey and more responsibility for the result. The $5M+ round can finance the integration. It cannot perform it.